Nancy Sharma1, Boris G Naraev, Eric G Engelman, M Bridget Zimmerman, David L Bushnell, Thomas M OʼDorisio, M Sue OʼDorisio, Yusuf Menda, Jan Müller-Brand, James R Howe, Thorvardur R Halfdanarson. 1. From the *Division of Hematology, Oncology, and Bone and Marrow Transplantation and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA; †Banner MD Anderson Cancer Center, Gilbert, AZ; ‡Medical Associates Clinic, Dubuque; and §Department of Biostatistics, College of Public Health, University of Iowa; ∥Department of Radiology, University of Iowa Hospitals and Clinics; ¶Iowa City Veterans Administration Medical Center; #Division of Endocrinology and Metabolism and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics; and **Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA; ††Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; ‡‡Division of Surgical Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA; and §§Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN.
Abstract
OBJECTIVES: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). METHODS: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. RESULTS: The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. CONCLUSIONS: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.
OBJECTIVES: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). METHODS: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. RESULTS: The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. CONCLUSIONS: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.
Authors: Andreas Klaus Pfeifer; Tine Gregersen; Henning Grønbæk; Carsten Palnæs Hansen; Jan Müller-Brand; Karin Herskind Bruun; Klaus Krogh; Andreas Kjær; Ulrich Knigge Journal: Neuroendocrinology Date: 2011-02-19 Impact factor: 4.914
Authors: Linda Villard; Anna Romer; Nicolas Marincek; Philippe Brunner; Michael T Koller; Christian Schindler; Quinn K T Ng; Helmut R Mäcke; Jan Müller-Brand; Christoph Rochlitz; Matthias Briel; Martin A Walter Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik Journal: J Am Coll Surg Date: 2012-10-11 Impact factor: 6.113
Authors: Derek K Smith; Lance Kates; Steffen Durinck; Nisha Patel; Eric W Stawiski; Noelyn Kljavin; Oded Foreman; Bence Sipos; Mark J Solloway; Bernard B Allan; Andrew S Peterson Journal: Cell Rep Med Date: 2020-08-25
Authors: Bryson W Katona; Giorgio A Roccaro; Michael C Soulen; Yu-Xiao Yang; Bonita J Bennett; Brian P Riff; Rebecca A Glynn; Damian Wild; Guillaume P Nicolas; Daniel A Pryma; Ursina R Teitelbaum; David C Metz Journal: Pancreas Date: 2017-10 Impact factor: 3.327
Authors: Jason M Heckert; Sarit T Kipnis; Shria Kumar; Samuel Botterbusch; Alice Alderson; Bonita Bennett; Caroline Creamer; Jennifer R Eads; Michael C Soulen; Daniel A Pryma; David A Mankoff; David C Metz; Bryson W Katona Journal: Oncologist Date: 2020-03-06
Authors: Rudolf A Werner; Harun Ilhan; Sebastian Lehner; László Papp; Norbert Zsótér; Imke Schatka; Dirk O Muegge; Mehrbod S Javadi; Takahiro Higuchi; Andreas K Buck; Peter Bartenstein; Frank Bengel; Markus Essler; Constantin Lapa; Ralph A Bundschuh Journal: Mol Imaging Biol Date: 2019-06 Impact factor: 3.488
Authors: M Albertelli; A Dotto; C Di Dato; P Malandrino; R Modica; A Versari; A Colao; D Ferone; A Faggiano Journal: Rev Endocr Metab Disord Date: 2021-09 Impact factor: 9.306